A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment
Public ClinicalTrials.gov record NCT04035226. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective, Multinational Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMID, and CD38 Monoclonal Antibody Treatment
Study identification
- NCT ID
- NCT04035226
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Lead sponsor
- Janssen-Cilag Ltd.
- Industry
- Enrollment
- 254 participants
Conditions and interventions
Conditions
Interventions
- No intervention Other
Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 1, 2019
- Primary completion
- Oct 26, 2022
- Completion
- Oct 26, 2022
- Last update posted
- Mar 29, 2025
2019 – 2022
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Oncology Institute of Hope and Innovation | Glendale | California | 91204 | — |
| Marin Cancer Center | Greenbrae | California | 94904 | — |
| Asclepes Research | Weeki Wachee | Florida | 34607 | — |
| Oncology Hematology Assoc of Central Illinois, P.C. d.b.a. Illinois CancerCare, P.C. | Peoria | Illinois | 61615 | — |
| Providence Cancer Center | Southfield | Michigan | 48075 | — |
| Central Care Cancer Center | Bolivar | Missouri | 65613 | — |
| Washington University School Of Medicine | St Louis | Missouri | 63110 | — |
| Optum Care | Las Vegas | Nevada | 89102 | — |
| Hunterdon Hematology Oncology | Flemington | New Jersey | 08822 | — |
| The Cancer Institute at St. Francis Hospital | East Hills | New York | 11548 | — |
| North Shore Hematology Oncology Associates, P.C. | East Setauket | New York | 11733 | — |
| The Ohio State University | Columbus | Ohio | 43210 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 63 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04035226, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 29, 2025 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04035226 live on ClinicalTrials.gov.